Advertisement

Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients

  • José Miguel Rivera-Caravaca
    Correspondence
    Corresponding author: William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom; Telephone number: 0151 794 9020
    Affiliations
    Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain

    Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
    Search for articles by this author
  • Wern Yew Ding
    Correspondence
    Corresponding author: William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom; Telephone number: 0151 794 9020
    Affiliations
    Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
    Search for articles by this author
  • Francisco Marín
    Affiliations
    Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain
    Search for articles by this author
  • Vanessa Roldán
    Affiliations
    Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, Murcia, Spain
    Search for articles by this author
  • Gregory Y.H. Lip
    Correspondence
    Corresponding author: William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom; Telephone number: 0151 794 9020
    Affiliations
    Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

    Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
    Search for articles by this author
  • Christina J.-Y. Lee MD, PhD; Christian Torp-Pedersen MD, DMSc
Published:December 21, 2021DOI:https://doi.org/10.1016/j.ejim.2021.12.014
      The CHA2DS2-VASc score is one of the most validated risk tools in atrial fibrillation (AF) [
      • Borre ED
      • Goode A
      • Raitz G
      • Shah B
      • Lowenstern A
      • Chatterjee R
      • et al.
      Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.
      ], and remains a simple and practical clinical score to aid decision-making. However, it has limitations in predicting the absolute stroke risk and its ability for identifying patients at risk of thromboembolism is modest.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Borre ED
        • Goode A
        • Raitz G
        • Shah B
        • Lowenstern A
        • Chatterjee R
        • et al.
        Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.
        Thromb Haemost. 2018; 118: 2171-2187
        • Lee CJ
        • Toft-Petersen AP
        • Ozenne B
        • Phelps M
        • Olesen JB
        • Ellinor PT
        • et al.
        Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach.
        Eur Heart J Cardiovasc Pharmacother. 2020;
        • Rivera-Caravaca JM
        • Roldán V
        • Esteve-Pastor MA
        • Valdés M
        • Vicente V
        • Lip GYH
        • et al.
        Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
        Thromb Haemost. 2017; 117: 1448-1454
        • Bousser MG
        • Bouthier J
        • Buller HR
        • Cohen AT
        • Crijns H
        • Davidson BL
        • et al.
        Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
        Lancet. 2008; 371: 315-321
        • Rivera-Caravaca JM
        • Esteve-Pastor MA
        • Marín F
        • Valdés M
        • Vicente V
        • Roldán V
        • et al.
        A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials.
        Mayo Clin Proc. 2018; 93: 1065-1073
        • de Vries TAC
        • Hirsh J
        • Xu K
        • Mallick I
        • Bhagirath VC
        • Eikelboom JW
        • et al.
        Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
        Thromb Haemost. 2020;
        • Chao TF
        • Lip GYH
        • Lin YJ
        • Chang SL
        • Lo LW
        • Hu YF
        • et al.
        Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
        Eur Heart J. 2019; 40: 1504-1514
        • Fauchier L
        • Bodin A
        • Bisson A
        • Herbert J
        • Spiesser P
        • Clementy N
        • et al.
        Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis.
        J Clin Med. 2020; 9
        • Yoon M
        • Yang PS
        • Jang E
        • Yu HT
        • Kim TH
        • Uhm JS
        • et al.
        Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
        Thromb Haemost. 2018; 118: 1296-1304
        • Chao TF
        • Liao JN
        • Tuan TC
        • Lin YJ
        • Chang SL
        • Lo LW
        • et al.
        Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.
        Thromb Haemost. 2019; 119: 1162-1170